Instructions

The model was developed on a sample of 250 patients from 9 Spanish hospitals. Patients were treated between 2013-2015.In 90% of the cases, patients received FOLFIRI-aflibercept as second-line therapy. The user must be aware that some patients were treated with FOLFIRI at adapted doses (no bolus, dose reduction), following the clinical practice patterns at each center.

Cox proportional hazards regression was used, verifying the constant effect of covariates. Finally, an internal validation by bootstrap was carried out.

References:

Fernández Montes A, López López C, Argilés Martínez G, Páez López D, López Muñoz AM, García Paredes B, Gutiérrez Abad D, Castañón López C, Jiménez Fonseca P, Gallego Plazas J, López Doldán MC, Martínez de Castro E, Sánchez Cánovas M, Tobeña Puyal M, Llorente Ayala B, Juez Martel I, López Flores M, Carmona-Bayonas A. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. Oncologist. 2019 May 30. doi: 10.1634/theoncologist.2018-0824.

Montes, et al. Prognostic Nomogram and Patterns of Use of FOLFIRI‐Aflibercept in Advanced Colorectal Cancer: A Real‐World Data Analysis. The Oncologist (2019): doi:10.1634/theoncologist.2018-0824